Stereoselective Synthesis of the C₅-C₁₈ Fragment of Halichomycin

Qingjiang Li,[†] Shiyong Mao,[†] Yuxin Cui,[†] and Yanxing Jia^{*,†,‡}

[†]State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China

[‡]State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China

Supporting Information

ABSTRACT: An efficient and convergent synthesis of the C_5-C_{18} fragment of halichomycin is reported. Butanolide fragment **6** was readily prepared stereoselectively from (*R*)-Roche ester through catalyst control; dienylic bromide domain 7 was synthesized from (*S*)-serine by substrate control. C_5-C_{18} fragment **2** was rapidly assembled through a stereoselective alkylation of the butanolide with the dienylic bromide, followed by functional group transformations.

H alichomycin, a structurally unique tricyclic macrolactam, is produced by a strain of *Streptomyces hygroscopicus* which was isolated from the gastrointestinal tract of the marine fish *Halichoeres bleekeri* by Numata and colleagues in 1994 (Figure 1).¹ Halichomycin exhibits potent cytotoxicity (ED_{50}



Figure 1. Structure of halichomycin (relative configuration).

0.13 μ g/mL) against a murine P388 lymphocytic leukemia cell line, which is of potential use as an anticancer drug.

Halichomycin represents a significant challenge to chemical synthesis owing to its extraordinary molecular architecture, embodying three intersecting ring systems which include a fully functionalized 11-membered ether ring (C ring) and a structurally unique 13/11-membered bicyclic hemimacrolactam (AB ring), 10 stereocenters including six contiguous stereocenters, and five double bonds. However, the absolute configuration of halichomycin has not been reported until now. The unique structural features and powerful biological activity of 1 make it an attractive target for total synthesis.² Wood reported the synthesis of the C_1-C_7 segment of halichomycin.^{2a} Hale proposed a biosynthetic route for ring formation in halichomycin and synthesized the AB-carbon backbone of halichomycin.^{2b} However, no total synthesis has been accomplished up to now. As part of our interest directed toward the total synthesis of bioactive natural products,³ we have embarked on the synthesis of halichomycin. In order to test the formation of the "strange"⁴ hemimacrolactam of



halichomycin, a concise and scalable synthesis of its backbone is needed. Herein, we report a synthetic strategy for the C_5-C_{18} fragment (2), which includes six contiguous stereocenters.

Our retrosynthetic analysis of halichomycin (1) is outlined in Scheme 1. The key compound 2 could be generated from an Evans asymmetric aldol reaction between aldehyde 3 and acylated oxazolidinone 4 followed by reduction. In order to introduce with stereocontrol the C₈ and C₂₅ vicinal carbon substituents of 3, butenolide 8 was used as the chiral template.⁵ The lactone 5 could be obtained through stereoselective α alkylation of 6 with bromide 7 from the β -face. Butyrolactone 6 could be accessed by conjugate addition of lithium dimethylcuprate to butenolide 8, which would be available from the Pu asymmetric addition of methyl propiolate to aldehydes,⁶ followed by Lindlar reduction. Dienylic bromide 7 would be obtained in optically pure form by manipulation of chiron derived originally from (*S*)-serine.

The synthesis of the known lactone **6** has been reported by many other groups.⁷ We developed a new method for the synthesis of **6** (Scheme 2). The known aldehyde **12** was prepared in 95% yield starting from the commercially available (*R*)-Roche ester **9**.⁸ According to the standard conditions reported by Pu, the (*S*)-BINOL-catalyzed asymmetric addition of ethyl propiolate **10** to aldehyde **12** led to the desired product **13** in 94% yield with a diastereomeric ratio of 11:1, which was impossible to separate by column chromatography.⁹ Lindlar reduction of alkyne **13** gave the corresponding *cis*-alkene, which was automatically converted into butenolide **8** during purification by flash column chromatography. Conjugate addition of Me₂CuLi to butenolide **8** gave the known exclusive product lactone **6**^{2b,7e} as a single stereoisomer in 85% yield.

The synthesis of C_9-C_{15} dienylic bromide 7 is shown in Scheme 3. The known alcohol 15 was prepared from (S)-serine

Received: January 11, 2012 Published: March 26, 2012

Scheme 1. Retrosynthetic Analysis of Halichomycin (1)



Scheme 2. Synthesis of Lactone 6



(11) in 57% overall yield.¹⁰ Methylation of alcohol 15 with iodomethane and Ag_2O in Et_2O afforded 16 in 90% yield.^{11,12} DIBAL reduction of the ester moiety in 16 followed by Swern oxidation of the derived alcohol provided aldehyde 17 in 80% yield, which further underwent a Horner–Wadsworth– Emmons olefination to afford 18 in 92% yield. DIBAL reduction of ester 18 followed by Swern oxidation provided the aldehyde 19 in 93% yield. (*Z*)-Selective olefination of aldehyde 19 using Still–Gennari's protocol provided diene 20 in quantitative yield.^{13,14} Reduction of ester 20 with DIBAL gave the corresponding allylic alcohol 21, which was subjected



to bromination following Roush's procedure to afford the dienylic bromide 7 in 99% yield.¹⁵

With the two fragments 6 and 7 in hand, the stage was set for the key α -alkylation reaction (Scheme 4). It smoothly afforded the desired coupling product 5 as a nearly 4.2:1¹⁶ inseparable diastereomers. It is worth mentioning that HMPA played an important role in this reaction, giving a higher conversion. Lactone 5 was reductively ring-opened with lithium borohydride to produce the diol 22 in 60% overall yield. Selective protection of the primary alcohol in 22 by using $Ac_2O/DMAP$, followed by protection the remaining secondary hydroxy group by using TBSOTf/2,6-lutidine, furnished fully protected compound 23 in 94% overall yield. Removal of the acetyl group in 23 employing K₂CO₃ in CH₃OH followed by IBX oxidation of the derived alcohol 24 provided aldehyde 3 in 96% yield. In order to promote the complete conversion of aldehyde 3 in the Evans aldol reaction, 17 it was essential to use the excess of propionimide enolate (see the Experimental Section). Finally, reductive removal of the oxazolidinone unit from 25 with LiBH₄ furnished the diol 2 in 95% yield.¹⁸

In conclusion, we have accomplished the synthesis of the C_5-C_{18} fragment (2) of halichomycin. The approach is highly convergent. The longest linear sequence is 20 steps, and the overall yield is an impressive 8.8%. The synthesis features an (*S*)-BINOL-catalyzed asymmetric addition of ethyl propiolate to aldehyde followed by reduction to form the butenolide 8, and stereocontrolled introduction of C_8 and C_{25} functional groups by using butenolide 8 as the chiral template.

EXPERIMENTAL SECTION

General Remarks. Flash column chromatography (FCC) was performed using silica gel (200–300 mesh) with solvents distilled prior to use. Petroleum ether is abbreviated to PE.





Compound 13. To a solution of (S)-BINOL (458 mg, 1.6 mmol), HMPA (1.4 mL, 8.0 mmol), and ethyl propiolate (1.63 mL, 16.0 mmol) in dry CH₂Cl₂ (48 mL) at rt under Ar was added Et₂Zn (16 mL, 1 M in hexane, 16.0 mmol). After the solution had been stirred for 16 h, Ti(O-i-Pr)₄ (1.2 mL, 4.0 mmol) was added and stirred for another 1 h. Then, 12 (1.30 g, 4.0 mmol) was added, and the reaction was allowed to proceed at rt for 4 h. The mixture was quenched with saturated NH₄Cl and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was purified by FCC (PE/EtOAc, 12:1) to give the product 13 (1.59 g, 94%): ¹H NMR (400 MHz, CDCl₃) δ 7.71–7.67 (m, 4H), 7.46–7.39 (m, 6H), 4.65 (t, J = 6.0 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 3.96 (dd, J = 4.0, 10.4 Hz, 1H), 3.63 (dd, J = 6.0, 10.4 Hz, 1H), 3.49 (d, J = 5.2 Hz, 1H), 2.07 (m, 1H), 1.33 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.07 (s, 9H); $^{13}\mathrm{C}$ NMR (100 MHz, CDCl₃) δ 153.3, 135.6, 135.5, 132.7, 132.6, 129.9, 127.8, 86.8, 77.4, 66.8, 66.1, 62.0, 40.4, 26.8, 19.1, 14.0, 12.9; HRMS (ESI) m/z calcd for C₂₅H₃₃O₄Si (M + H)⁺ 425.2143, found 425.2138; IR (KBr) 3032, 2961, 2859, 2234, 1713, 1470, 1427, 1390, 1366, 1246, 1110, 1037, 823, 742, 704, 614, 505 cm⁻¹.

Compound 8. To a solution of 13 (936 mg, 2.21 mmol) in methanol (30 mL) was added Lindlar catalyst (221 mg) at rt, and then the flask was evacuated and filled with hydrogen three times. The suspension was stirred under H₂ at rt for 11 h and then filtered through a pad of Celite and concentrated. The residue was purified by FCC (PE/EtOAc, 10:1) to give butenolide 8 (805 mg, 96%): ¹H NMR (400 MHz, CDCl₃) δ 7.67–7.63 (m, 4H), 7.47–7.38 (m, 7H), 6.11 (dd, *J* = 1.6, 5.6 Hz, 1H), 5.23 (dt, *J* = 1.6, 6.0 Hz, 1H), 3.81 (dd, *J* = 4.4, 10.4 Hz, 1H), 3.59 (dd, *J* = 6.0, 10.4 Hz, 1H), 2.16 (m, 1H),

1.07 (s, 9H), 0.90 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.0, 155.3, 135.6, 135.5, 133.1, 133.0, 129.9, 129.8, 127.8, 121.9, 84.6, 65.1, 39.2, 26.9, 19.3, 11.7; $[\alpha]_{D}^{26} - 37.6$ (c 1.07, MeOH); HRMS (ESI) m/z calcd for C₂₃H₃₂NO₃Si (M + NH₄)⁺ 398.2146, found 398.2149; IR (KBr) 2959, 2931, 2858, 1784, 1757, 1471, 1428, 1162, 1110, 1089, 1029, 820, 742, 704, 614, 505 cm⁻¹.

Compound 6. To a slurry of CuI (1.72 g, 9.05 mmol) in Et_2O (25 mL) was added MeLi·LiBr (10.9 mL, 1.5 M in ether, 16.2 mmol) at 0 $^{\circ}$ C under Ar. The solution was cooled to -30 $^{\circ}$ C, and then 8 (686 mg, 1.81 mmol) in Et₂O (5 mL) was added. The mixture was stirred at -20 °C for 1 h and quenched with saturated NH₄Cl. Ammonium hydroxide was added, and the aqueous layers were extracted with ether. The combined organic extracts were washed with brine, dried over Na₂SO₄, and evaporated. The residue was purified by FCC (PE/ EtOAc, 6:1) to give 6 (609 mg, 85%). The data of ¹H and ¹³C NMR are consistent with that reported by Hale:^{2b} ¹H NMR (400 MHz, $CDCl_3$) δ 7.69–7.66 (m, 4H), 7.46–7.37 (m, 6H), 4.15 (t, J = 6.4 Hz, 1H), 3.70 (dd, J = 1.6, 5.2 Hz, 2H), 2.68 (dd, J = 8.8, 17.2 Hz, 1H), 2.49 (m, 1H), 2.18 (dd, J = 8.0, 17.6 Hz, 1H), 1.99 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H), 1.08 (s, 9H), 1.01 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.4, 135.5, 133.4, 133.3, 129.7, 127.7, 88.3, 64.9, 39.4, 37.1, 32.2, 26.8, 19.3, 19.2, 13.0; $[\alpha]_{D}^{26}$ +23.9 (c 0.50, MeOH); HRMS (ESI) m/z calcd for $C_{24}H_{36}NO_3Si$ (M + NH₄)⁺ 414.2459, found 414.2453; IR (KBr) 2960, 2929, 2857, 1779, 1463, 1427, 1214, 1173, 1110, 1007, 823, 742, 704, 614, 505 cm⁻¹

Compound 16. To a solution of **15** (5.86 g, 25.0 mmol), MeI (31 mL, 500 mmol) in Et₂O (300 mL) was added Ag₂O (17.4 g, 75.0 mmol). The reaction mixture was stirred for 10 h at rt, filtered, and concentrated, and the residue was purified by FCC (PE/EtOAc, 8:1) to give **16** (5.6 g, 90%): ¹H NMR (400 MHz, CDCl₃) δ 3.84 (s, 3H), 3.72 (s, 3H), 3.41 (s, 3H), 0.84 (s, 9H), 0.02 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 82.0, 64.0, 58.5, 51.7, 25.7, 18.2, -5.5, -5.6; $[\alpha]_{D}^{23}$ -24.3 (c 0.40, CH₂Cl₂), the optical rotation of its enantiomer [lit.¹¹ $[\alpha]_{D}^{28}$ +20.3 (c 1.9, CH₂Cl₂)]; HRMS (ESI) *m/z* calcd for C₁₁H₂₄O₄SiNa (M + Na)⁺ 271.1336, found 271.1333; IR (KBr) 2954, 2931, 2858, 1756, 1464, 1257, 1201, 1121, 839, 779 cm⁻¹.

Compound 17. To a solution of 16 (4.02 g, 16.2 mmol) in Et₂O (110 mL) at -78 °C was added DIBAL-H (19.5 mL, 1 M in hexane, 19.5 mmol). After the starting material was consumed via TLC analysis, the reaction was quenched with MeOH, warmed to rt, and poured into satd aq potassium sodium tartrate solution. The mixture was vigorously stirred until the phase separation occurred and extracted with Et₂O. The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated to give the corresponding alcohol.

To a solution of $(\text{COCl})_2$ (2.9 mL, 32.4 mmol) in CH₂Cl₂ (120 mL) at -78 °C was added DMSO (4.6 mL, 64.8 mmol). After being stirred for 10 min, the alcohol was added to CH₂Cl₂ (15 mL). After 45 min, Et₃N (13.6 mL, 97.2 mmol) was added, and the solution was warmed to rt. After 30 min, the reaction was quenched with water and extracted with CH₂Cl₂. The combined organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by FCC (PE/EtOAc, 20:1) to give the aldehyde 17 (2.83 g, 80%): ¹H NMR (400 MHz, CDCl₃) δ 9.71 (s, 1H), 3.91 (d, *J* = 4.4 Hz, 2H), 3.66 (t, *J* = 4.4 Hz, 1H), 3.50 (s, 3H), 0.88 (s, 9H), 0.06 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 202.9, 86.5, 62.5, 58.6, 25.8, 18.3, -5.5; $[\alpha]_{D}^{22} - 32.0$ (*c* 0.40, CH₂Cl₂); HRMS (ESI) *m/z* calcd for C₁₀H₂₃O₃Si (M + H)⁺ 219.1411, found 219.1411; IR (KBr) 2954, 2931, 2858, 1737, 1467, 1256, 1114, 838, 778 cm⁻¹.

Compound 18. To a solution of NaH (524 mg, 13.1 mmol, 60% in mineral oil) in THF (25 mL) at 0 °C was added triethyl phosphonoacetate (2.62 mL, 13.2 mmol). After being stirred for 10 min, aldehyde 17 (2.62 g, 12.0 mmol) in THF (5 mL) was added. The reaction mixture was warmed to rt and then heated at reflux for 1 h. The solution was cooled to rt, diluted with water, and extracted with EtOAc. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by FCC (PE/EtOAc, 40:1) to give **18** (3.18 g, 92%): ¹H NMR (400 MHz, CDCl₃) δ 6.81 (dd, *J* = 5.6, 16.0 Hz, 1H), 6.02 (dd, *J* = 1.2, 16.0 Hz, 1H), 4.18 (q, *J* = 7.2 Hz, 2H), 3.82 (m, 1H), 3.67 (dd, *J* = 6.0, 10.4 Hz,

1H), 3.58 (dd, J = 5.6, 10.4 Hz, 1H), 3.35 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.0, 145.4, 122.8, 81.5, 65.3, 60.3, 57.7, 25.8, 18.2, 14.2, -5.4, -5.5; $[\alpha]_{D}^{25}$ -8.0 (c 0.43, CH₂Cl₂); HRMS (ESI) m/z calcd for C₁₄H₃₂NO₄Si (M + NH₄)⁺ 306.2095, found 306.2089; IR (KBr) 2955, 2931, 2859, 1724, 1660, 1467, 1366, 1303, 1261, 1172, 1137, 1114, 1041, 984, 839, 779 cm⁻¹.

Compound 19. The ester **18** (1.37 g, 4.76 mmol) was converted into aldehyde **19** (1.08 g, 93% for two steps) by DIBAL reduction and Swern oxidation of the corresponding alcohol as described for compound **17**.

Corresponding alcohol S2: $[\alpha]_{D}^{23} - 15.7$ (*c* 0.38, CH₂Cl₂); HRMS (ESI) *m/z* calcd for C₁₂H₂₇O₃Si (M + H)⁺ 247.1724, found 247.1724; IR (KBr) 3416, 2954, 2930, 2858, 1464, 1255, 1096, 838, 777 cm⁻¹.

19: ¹H NMR (400 MHz, CDCl₃) δ 9.54 (dd, J = 1.2, 8.0 Hz, 1H), 6.72 (dd, J = 5.6, 16.0 Hz, 1H), 6.26 (ddd, J = 1.2, 8.0, 16.0 Hz, 1H), 3.92 (dd, J = 5.2, 10.8 Hz, 1H), 3.72 (m, 1H), 3.59 (dd, J = 6.0, 10.4 Hz, 1H), 3.34 (s, 3H), 0.83 (s, 9H), 0.01 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 193.0, 154.4, 132.9, 81.3, 64.8, 57.8, 25.7, 18.1, -5.5, -5.6; $[\alpha]_{22}^{D2}$ +14.4 (c 0.32, CH₂Cl₂); HRMS (ESI) m/z calcd for C₁₂H₂₈NO₃Si (M + NH₄)⁺ 262.1833, found 262.1831; IR (KBr) 2957, 2931, 2858, 1724, 1696, 1468, 1256, 1117, 980, 839, 779 cm⁻¹.

Compound 20. To a solution of ethyl 2-[bis(2,2,2-trifluoroethyl) phosphono]propionate (1.15 g, 3.33 mmol) and 18-crown-6 (3.38 g, 12.8 mmol) in THF (50 mL) at -78 °C was added KHMDS (6.15 mL, 0.5 M in toluene, 3.07 mmol) under Ar. After the solution was stirred for 1 h, aldehyde 19 (624 mg, 2.56 mmol) in THF (5 mL) was added. The reaction mixture was stirred for another 1 h, quenched with saturated NH₄Cl, and extracted with EtOAc. The extract was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by FCC (PE/EtOAc, 30:1) to give 20 (840 mg, quant, Z:E > 30:1): ¹H NMR (400 MHz, CDCl₃) δ 7.25 (dd, J = 11.2, 15.2 Hz, 1H), 6.37 (d, J = 11.2 Hz, 1H), 5.69 (dd, J = 7.2, 15.2 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 3.72 (m, 1H), 3.64 (dd, J = 6.4, 10.4 Hz, 1H), 3.56 (dd, J = 5.2, 10.4 Hz, 1H), 3.29 (s, 3H), 1.93 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 0.84 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.3, 138.8, 137.0, 130.0, 126.9, 82.7, 66.0, 60.2, 56.9, 25.8, 20.6, 18.2, 14.1, -5.3, -5.4; $[\alpha]_D^{23}$ -23.0 (c 0.49, CH₂Cl₂); HRMS (ESI) m/z calcd for $C_{17}H_{36}NO_4Si$ (M + NH₄)⁺ 346.2408, found 346.2416; IR (KBr) 2954, 2929, 2858, 1712, 1464, 1377,1255, 1209, 1162, 1108, 838, 777 cm⁻¹.

Compound 21. DIBAL reduction of **20** (867 mg, 2.64 mol) gave **21** (624 mg, 83%) described as above: ¹H NMR (400 MHz, CDCl₃) δ 6.51 (dd, *J* = 11.2, 15.2 Hz, 1H), 5.93 (d, *J* = 11.2 Hz, 1H), 5.47 (dd, *J* = 7.2, 15.2 Hz, 1H), 4.24 (d, *J* = 2.8 Hz, 2H), 3.70–3.62 (m, 2H), 3.55 (dd, *J* = 4.8, 10.4 Hz, 1H), 3.31 (s, 3H), 1.86 (s, 3H), 1.75 (brs, 1H), 0.87 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 137.4, 130.6, 128.1, 127.1, 83.0, 66.2, 61.5, 56.9, 25.9, 21.4, 18.3, -5.3 (2C); $[\alpha]_D^{24}$ –28.6 (*c* 0.48, CH₂Cl₂); HRMS (ESI) *m/z* calcd for C₁₅H₃₁O₃Si (M + H)⁺ 287.2037, found 287.2034; IR (KBr) 3418, 2953, 2929, 2858, 1466, 1254, 1111, 1007, 969, 838, 778 cm⁻¹.

Compound 7. To a stirred solution of 21 (572 mg, 2.0 mmol) and triethylamine (0.44 mL, 3.0 mmol) in CH_2Cl_2 (4 mL) at 0 °C was added Me₂O (453 mg, 2.6 mmol). After 15 min, the reaction was diluted with acetone (4 mL) and charged with LiBr (1.05 g, 12.0 mmol). After the mixture was stirred for 1.5 h at 25 °C, the solvents were removed in vacuo. The concentrate was then rinsed out of the flask and partitioned between saturated NH4Cl and EtOAc. The aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and evaporated. The residue was purified by FCC (PE/EtOAc, 20:1) to give 7 (691 mg, 99%): ¹H NMR (400 MHz, CDCl₃) δ 6.48 (dd, J = 11.2, 15.2 Hz, 1H), 5.99 (d, J = 10.8 Hz, 1H), 5.61 (dd, J = 7.2, 15.2 Hz, 1H), 4.11 (dd, J = 10.0, 13.2 Hz, 2H), 3.76-3.65 (m, 2H), 3.58 (dd, J = 4.8, 10.0 Hz, 1H), 3.34 (s, 3H), 1.92 (s, 3H), 0.88 (s, 9H),0.06 (s, 3H), 0.05 (s, 3H); 13 C NMR (100 MHz, CDCl₃) δ 133.6, 132.5, 129.5, 127.6, 82.9, 66.0, 57.1, 31.9, 25.9, 22.1, 18.4, -5.2, -5.3; $[\alpha]_{\rm D}^{21}$ -24.0 (c 0.20, CH₂Cl₂); HRMS (ESI) m/z calcd for

 $\rm C_{15}H_{33}NBrO_2Si~(M$ + $\rm NH_4)^+$ 366.1458, found 366.1463; IR (KBr) 2954, 2928, 2856, 1254, 1134, 1110, 838, 777 $\rm cm^{-1}.$

Compound 22. To a solution of 6 (522 mg, 1.32 mmol) and HMPA (0.46 mL, 2.64 mmol) in THF (30 mL) under Ar at -78 °C was added LHMDS (2.64 mL, 1.0 M in THF, 2.64 mmol). The solution was stirred at -78 °C for 1 h, and 7 (552 mg, 1.58 mmol) in THF (5 mL) was added. After 45 min, the reaction mixture was quenched with saturated NaHCO₃, and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by FCC (PE/ EtOAc, 15:1) to give the inseparable coupling product 5 and its isomers (781 mg, 89% overall yield): ¹H NMR (400 MHz, CDCl₃) δ 7.66-7.63 (m, 4H), 7.44-7.36 (m, 6H), 6.44 (dd, J = 12.0, 14.0 Hz, 1H), 5.97 (d, J = 10.8 Hz, 1H), 5.48 (dd, J = 6.4, 14.8 Hz, 1H), 4.03 (t, J = 7.2 Hz, 1H), 3.69–3.56 (m, 5H), 3.29 (s, 3H), 2.68 (m, 1H), 2.51-2.37 (m, 2H), 2.12-1.96 (m, 2H), 1.79 (s, 3H), 1.11 (d, J = 6.0 Hz, 3H), 1.05 (s, 9H), 0.98 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 178.1, 135.5, 135.4, 133.5, 133.4, 130.1, 129.7, 128.5, 127.7, 127.6, 85.8, 83.2, 66.4, 65.0, 56.8, 46.7, 39.7, 38.7, 32.0, 26.9, 25.9, 23.7, 19.3, 18.4, 18.1, 13.1, -5.2, -5.3; HRMS (ESI) m/z calcd for $C_{39}H_{64}NO_5Si_2$ (M + NH₄)⁺ 682.4318, found 682.4329.

To a stirred solution of 5 (781 mg, 1.17 mmol) in THF (20 mL) and MeOH (0.2 mL) at 0 °C was added LiBH₄ (257 mg, 11.7 mmol). The reaction mixture was warmed to rt, stirred for 1.5 h, cooled to 0 °C, carefully quenched with HCl (1.0 M), and extracted with EtOAc. The extract was washed with brine, dried over Na₂SO₄, and concentrated. The residue was purified by FCC (PE/EtOAc, 8:1) to give 22 (530 mg, 67%): ¹H NMR (400 MHz, CDCl₃) δ 7.70-7.68 (m, 4H), 7.47–7.39 (m, 6H), 6.51 (dd, J = 11.2, 14.8 Hz, 1H), 5.93 (d, J = 11.2 Hz, 1H), 5.42 (dd, J = 7.2, 14.8 Hz, 1H), 3.93 (dd, J = 3.2, 10.4 Hz, 1H), 3.74-3.41 (m, 8H), 3.32 (s, 3H), 2.36-2.16 (m, 3H), 2.06-1.92 (m, 3H), 1.86 (s, 3H), 1.11 (d, J = 6.8 Hz, 3H), 1.07 (s, 9H), 0.91 (s, 9H), 0.86 (d, J = 7.2 Hz, 3H), 0.07 (s, 6H); ¹³C NMR (100 MHz, $CDCl_3$ δ 139.4, 135.6, 135.5, 132.6, 132.5, 129.9, 129.5, 128.5, 127.8, 127.7, 126.0, 83.3, 79.3, 67.2, 66.5, 64.0, 56.7, 39.4, 36.8, 35.9, 30.1, 26.8, 25.9, 24.0, 19.0, 18.4, 15.3, 12.5, -5.2, -5.3; $\lceil \alpha \rceil_{\rm D}^{23}$ -21.6 (c 0.43, CH₂Cl₂); HRMS (ESI) m/z calcd for C₃₉H₆₄O₅Si₂Na (M + Na)⁴ 691.4184, found 691.4199; IR (KBr) 2956, 2928, 2857, 1469, 1428, 1256, 1110, 1084, 837, 747, 703, 505 cm⁻¹

Compound 23. To a solution of **22** (339 mg, 0.51 mmol), pyridine (82 μ L, 1.02 mmol), and DMAP (12 mg, 0.010 mmol) in CH₂Cl₂ (8 mL) at 0 °C was added Ac₂O (73 μ L, 0.77 mmol). The reaction mixture was stirred at rt for 1 h, quenched with saturated NH₄Cl, and extracted with EtOAc. The extract was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by FCC (PE/EtOAc, 10:1) to give the primary alcohol Ac-protected product **S3** (349 mg, 97%): $[\alpha]_{23}^{D3}$ –13.2 (*c* 0.26, CH₂Cl₂); HRMS (ESI) *m*/*z* calcd for C₄₁H₆₆O₆Si₂Na (M + Na)⁺ 733.4290, found 733.4282; IR (KBr) 2961, 2928, 2857, 1338, 1260, 1109, 751, 704 cm⁻¹.

To a stirred solution of S3 (304 mg, 0.43 mmol) and 2,6-lutidine (0.30 mL, 2.58 mmol) in CH₂Cl₂ (8 mL) at 0 °C was added TBSOTf (0.30 mL, 1.29 mmol). The reaction mixture was stirred at rt for 1.5 h, quenched with saturated NH4Cl, and extracted with EtOAc. The extract was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by FCC (PE/EtOAc, 20:1) to give 23 (342 mg, 97%): ¹H NMR (400 MHz, CDCl₃) δ 7.68–7.64 (m, 4H), 7.42– 7.33 (m, 6H), 6.40 (dd, J = 11.2, 15.2 Hz, 1H), 5.92 (d, J = 11.2 Hz, 1H), 5.42 (dd, J = 7.2, 15.2 Hz, 1H), 3.94 (dd, J = 3.6, 11.2 Hz, 1H), 3.84–3.58 (m, 6H), 3.44 (dd, J = 8.4, 9.2 Hz, 1H), 3.33 (s, 3H), 2.35– 2.21 (m, 2H), 2.11 (m, 1H), 2.01 (m, 1H), 1.97 (s, 3H), 1.87 (m, 1H), 1.78 (s, 3H), 1.06 (s, 9H), 1.00 (dd, J = 3.2, 6.8 Hz, 3H), 0.91 (dd, J = 1.2, 7.2 Hz, 3H), 0.89 (s, 9H), 0.79 (s, 9H), 0.06-0.02 (9H), -0.09 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 137.7, 135.6 (2C), 134.0, 133.9, 129.5 (2C), 129.0, 128.8, 127.6, 126.9, 83.3, 77.8, 66.6 (2C), 64.9, 56.8, 40.2, 36.4, 35.5, 30.5, 26.9, 26.1, 25.9, 23.8, 20.9, 19.3, 18.4, 18.2, 14.5, 13.2, -3.8, -4.4, -5.2, -5.3; $[\alpha]_{D}^{23}$ +18.2 (c 0.22, CH₂Cl₂); HRMS (ESI) m/z calcd for $C_{47}H_{80}O_6Si_3Na$ (M + Na)⁺ 847.5155,

found 847.5152; IR (KBr) 2927, 2856, 1730, 1466, 1262, 1108, 752 $\rm cm^{-1}.$

Compound 24. To a solution of 23 (313 mg, 0.38 mmol) in MeOH (5 mL) was added K₂CO₃ (262 mg, 1.90 mmol) at rt. After being stirred for 5 h, the reaction was diluted with EtOAc and washed with 0.1 M NaOH (aq) solution. The aqueous layer was extracted with EtOAc, and the combined organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by FCC (PE/EtOAc, 15:1) to give 24 (290 mg, 97%): ¹H NMR (400 MHz, CDCl₃) δ 7.68-7.65 (m, 4H), 7.43-7.34 (m, 6H), 6.47 (dd, J = 11.2, 15.2 Hz, 1H), 5.93 (d, J = 10.8 Hz, 1H), 5.42 (dd, J = 7.2, 15.2 Hz, 1H), 3.85 (dd, J = 5.2, 10.0 Hz, 1H), 3.73-3.43 (m, 6H), 3.35 (dd, J = 6.0, 11.2 Hz, 1H), 3.32 (s, 3H), 2.33 (m, 1H), 2.17 (m, 1H), 2.02 (m, 1H), 1.92-1.90 (m, 2H), 1.80 (s, 3H), 1.07 (s, 9H), 1.03 (d, J = 6.8 Hz, 3H), 0.90 (s, 12H), 0.79 (s, 9H), 0.07–0.03 (9H), -0.08 (s, 3H); ¹³C NMR (100 MHz. CDCl₃) δ 139.2, 135.7, 134.1, 134.0, 129.5, 129.4, 128.9, 127.6, 126.4, 83.3, 78.1, 66.7, 66.5, 63.7, 56.7, 40.2, 38.9, 36.6, 31.0, 27.0, 26.1, 26.0, 24.0, 19.3, 18.4, 18.2, 14.8, 13.6, -3.7, -4.4, -5.2, -5.3; $[\alpha]_{\rm D}^{23}$ +10.7 (c 0.21, CH₂Cl₂); HRMS (ESI) m/z calcd for C₄₅H₈₂NO₅Si₃ (M + NH4)+ 800.5495, found 800.5479; IR (KBr) 2955, 2923, 2856, 1463, 1254, 1109, 1033, 1006, 836, 774, 702 cm⁻¹.

Compound 3. To a solution of 24 (221 mg, 0.28 mmol) in DMSO (6 mL) was added IBX (118 mg, 0.42 mmol) at rt. After 2.5 h, the reaction mixture was diluted with water (20 mL), filtered, and extracted with EtOAc. The combined organic extracts were washed with water, brine, dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was purified by FCC (PE/EtOAc, 30:1) to give 3 (216 mg, 99%). ¹H NMR (400 MHz, CDCl₃) δ 9.52 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 7.6 Hz, 4H), 7.44-7.35 (m, 6H), 6.46 (dd, J = 11.2, 15.2 Hz, 1H), 5.89 (d, J = 11.2 Hz, 1H), 5.44 (dd, J = 7.2, 15.2 Hz, 1H), 3.79–3.56 (m, 5H), 3.44 (dd, J = 8.0, 10.0 Hz, 1H), 3.33 (s, 3H), 2.67-2.58 (m, 2H), 2.31 (m, 1H), 2.15 (m, 1H), 1.96 (m, 1H), 1.77 (s, 3H), 1.06 (s, 9H), 0.96 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 7.6Hz, 3H), 0.89 (s, 9H), 0.81 (s, 9H), 0.06-0.03 (9H), -0.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 204.1, 135.9, 135.6, 133.9, 133.8, 129.7, 129.6 (2C), 128.7, 127.6, 126.9, 83.2, 77.2, 66.5, 66.2, 56.9, 50.8, 40.1, 36.7, 29.4, 26.9, 26.0, 25.9, 23.9, 19.2, 18.4, 18.2, 14.3, 13.9, -3.9, -4.4, -5.2, -5.3; $[\alpha]_{D}^{24}$ +14.2 (c 0.16, CH₂Cl₂); HRMS (ESI) m/zcalcd for C45H80NO5Si3 (M + NH4)+ 798.5339, found 798.5343; IR (KBr) 2955, 2926, 2855, 1729, 1463, 1256, 1110, 837, 774 cm⁻¹

Compound 25. To a solution of (4R,5S)-4-methyl-5-phenyl-3propionyl-2-oxazolidinone (4) (378 mg, 1.62 mmol) in CH₂Cl₂ (5.5 mL) at 0 °C under Ar were successively added Bu₂BOTf (1.62 mL, 1 M in CH₂Cl₂, 1.62 mmol) and triethylamine (0.28 mL, 1.94 mmol). After the solution was stirred at 0 °C for 45 min, 3 (158 mg, 0.202 mmol) in CH₂Cl₂ (2 mL) was added at -78 °C. The resulting mixture was stirred for 1 h, warmed to rt, stirred overnight, and quenched with phosphate buffer (4 mL, pH = 7) followed by addition of MeOH (1 mL)mL). To the resulting slurry was then added slowly 3 mL of a 2:1 v/v mixture of MeOH/30% aq H2O2, and the mixture was stirred vigorously for 4 h. The reaction was then extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was purified by FCC (PE/EtOAc, 12:1) to give 25 (121 mg, 59%): ¹H NMR (400 MHz, CDCl₃) δ 7.68-7.65 (m, 4H), 7.42-7.34 (m, 9H), 7.22 (d, J = 6.8 Hz, 2H), 6.61 (dd, J = 11.2, 15.2 Hz, 1H), 5.97 (d, J = 10.8 Hz, 1H), 5.55 (d, J = 7.2 Hz, 1H), 5.47 (dd, J = 7.2, 15.2 Hz, 1H), 4.72 (m, 1H), 3.88–3.80 (m, 3H), 3.76–3.58 (m, 4H), 3.45 (t, J = 9.2 Hz, 1H), 3.34 (s, 3H), 2.64 (t, J = 12.8 Hz, 1H), 2.30–2.03 (m, 5H), 1.86 (s, 3H), 1.26 (d, J = 6.4 Hz, 3H), 1.07 (s, 9H), 1.02 (d, J = 7.2 Hz, 3H), 1.00 (d, J = 7.6 Hz, 3H), 0.90 (s, 9H), 0.84 (d, J = 6.4 Hz, 3H), 0.80 (s, 9H), 0.07–0.06 (9H), -0.08 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.7, 152.1, 139.4, 135.6, 135.5, 133.9 (2C), 133.2, 129.5, 129.3, 128.7 (3C), 127.6, 126.7, 125.5, 83.2, 79.2, 78.7, 73.3, 67.0, 66.6, 56.8, 54.6, 41.2, 41.1, 36.1, 34.3, 30.4, 27.0, 26.2, 26.0, 23.7, 19.3, 18.4, 18.3, 14.2 (2C), 14.0, 13.5, -3.3, -4.2, -5.1, -5.3; $[\alpha]_{\rm D}^{24}$ +21.2 (c 0.44, CH₂Cl₂); HRMS (ESI) m/z calcd for C₅₈H₉₅N₂O₈Si₃ $(M + NH_4)^+$ 1031.6391, found 1031.6410; IR (KBr) 2956, 2930, 2857, 1786, 1697, 1462, 1345, 1254, 1194, 1112, 1091, 1027, 836, 774, 702 cm⁻¹.

Compound 2. Compound 2 was prepared from 25 (23 mg, 0.023 mmol) as described for compound 22 in Et₂O/H₂O (160:1): FCC (PE/EtOAc, 6:1), yield (18.3 mg, 95%); ¹H NMR (400 MHz, CDCl₃) δ 7.67–7.64 (m, 4H), 7.42–7.35 (m, 6H), 6.50 (dd, *J* = 10.8, 14.8 Hz, 1H), 5.87 (d, *J* = 10.8 Hz, 1H), 5.44 (dd, *J* = 6.8, 14.8 Hz, 1H), 3.80 (dd, *J* = 6.0, 10.0 Hz, 1H), 3.72–3.56 (m, 7H), 3.45 (t, *J* = 8.8 Hz, 1H), 3.33 (s, 3H), 2.41–2.01 (m, 7H), 1.82 (s, 3H), 1.77 (m, 1H), 1.06 (s, 9H), 1.01 (d, *J* = 6.8 Hz, 3H), 0.94–0.89 (m, 15H), 0.79 (s, 9H), 0.06–0.05 (9H), -0.06 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.6, 135.6, 133.9 (2C), 129.5, 129.2, 128.8, 127.6, 126.1, 83.0, 78.9, 75.9, 67.5, 66.8, 66.7, 56.9, 41.2, 37.4, 36.9, 34.4, 30.6, 26.9, 26.2, 26.0, 24.0, 19.3, 18.5, 18.4, 13.6 (2C), 11.1, -3.3, -4.2, -5.2, -5.3; [α]²_D² +20.0 (*c* 0.37, CH₂Cl₂); HRMS (ESI) *m*/*z* calcd for C₄₈H₈₄O₆Si₃Na (M + Na)⁺ 863.5468, found 863.5470; IR (KBr) 3447, 2956, 2929, 2857, 1468, 1254, 1110, 1084, 1026, 836, 776, 703 cm⁻¹.

ASSOCIATED CONTENT

S Supporting Information

Copies of spectra for compounds 2, 3, 5-8, 12, 13, and 15-25, and related compounds S1, S2, and S3. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: yxjia@bjmu.edu.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This research was supported by the National Natural Science Foundation of China (Nos. 20972007, 20802005), the National Basic Research Program of China (973 Program, NO. 2010CB833200), and NCET.

REFERENCES

 Takahashi, C.; Takada, T.; Yamada, T.; Minoura, K.; Uchida, K.; Matsumura, E.; Numata, A. *Tetrahedron Lett.* **1994**, *35*, 5013–5014.
(a) McCann, E. E.; Janes, G.; Ortsey, C.; Wood, J. L. *Tetrahedron Lett.* **1997**, *38*, 303–304.
(b) Hale, K. J.; Dimopoulos, P.; Cheung, M. L. F.; Frigerio, M.; Steed, J. W.; Levett, P. C. Org. Lett. **2002**, *4*, 897– 000

(3) (a) Xu, Z.; Li, Q.; Zhang, L.; Jia, Y. J. Org. Chem. 2009, 74, 6859–6862; Correction J. Org. Chem. 2010, 75, 6316. (b) Xu, Z.; Hu, W.; Liu, Q.; Zhang, L.; Jia, Y. J. Org. Chem. 2010, 75, 7626–7635. (c) Hu, W.; Zhang, F.; Xu, Z.; Liu, Q.; Cui, Y.; Jia, Y. Org. Lett. 2010, 12, 956–959. (d) Liu, Q.; Jia, Y. Org. Lett. 2011, 13, 4810–4813. (e) Li, Q.; Jiang, J.; Fan, A.; Cui, Y.; Jia, Y. Org. Lett. 2011, 13, 312–315. (f) Qin, H.; Xu, Z.; Cui, Y.; Jia, Y. Org. Lett. 2011, 50, 4447–4449. (g) Zhang, F.; Jia, Y. Tetrahedron 2009, 65, 6840–6843.

(4) Kobayashi, J.; Ishibashi, M. Comprehensive Natural Product Chemistry; Barton, D., Nakanishi, K., Meth-Cohn, O., Eds.; Pergamon: Oxford, 1999; Vol. 8, Chapter 8.07, p 416.

(5) (a) Hanessian, S.; Cooke, N. G.; DeHoff, B.; Sakito, Y. J. Am. Chem. Soc. **1990**, 112, 5276–5290. (b) Hanessian, S.; Murray, P. J. Tetrahedron **1987**, 43, 5055–5072.

(6) (a) Gao, G.; Wang, Q.; Yu, X.-Q.; Xie, R.-G.; Pu, L. Angew. Chem., Int. Ed. 2006, 45, 122–125. (b) Rajaram, A. R.; Pu, L. Org. Lett. 2006, 8, 2019–2021.

(7) (a) See refs 2b and 5a. (b) Taschner, M. J.; Aminbhavi, A. S. *Tetrahedron Lett.* 1989, 30, 1029–1032. (c) Kelly, T. R.; Chandrakumar, N. S. *Tetrahedron Lett.* 1985, 26, 2173–2176. (d) Taschner, M. J.; Black, D. J. J. Am. Chem. Soc. 1988, 110, 6892–6893. (e) Ziegler, F. E.; Becker, M. R. J. Org. Chem. 1990, 55, 2800–2805. (f) Mihovilovic, M. D.; Rudroff, F.; Grötzl, B.; Stanetty, P. *Eur. J. Org. Chem.* 2005, *5*, 809–816.

The Journal of Organic Chemistry

(8) Fürstner, A.; Kattnig, E.; Lepage, O. J. Am. Chem. Soc. 2006, 128, 9194-9204.

(9) The diastereomeric ratio was determined by ¹H NMR.

(10) (a) Yokokawa, F.; Inaizumi, A.; Shioiri, T. *Tetrahedron* 2005, *61*, 1459–1480. (b) Azuma, H.; Takao, R.; Niiro, H.; Shikata, K.; Tamagaki, S.; Tachibana, T.; Ogino, K. J. Org. Chem. 2003, *68*, 2790–2797. (c) Mukaiyama, T.; Shiina, I.; Iwadare, H.; Saitoh, M.; Nishimura, T.; Ohkawa, N.; Sakoh, H.; Nishimura, K.; Tani, Y.; Hasegawa, M.; Yamada, K.; Saitoh, K. Chem.—Eur. J. 1999, *5*, 121–161.

(11) The solvent played an important role in the O-methylation reaction, and the ether proved to be the best choice of solvent. The 1,2-silyl migration product was the main side product.

(12) The optical rotation of 16 $[[\alpha]^{23}_{D} = -24.3 (c \ 0.4, CH_2Cl_2)]$ is opposite to its enantiomer; see: Shapira, M.; Gutman, A. L. *Tetrahedron: Asymmetry* 1994, *5*, 1689–1700.

(13) (a) Bennani, Y. L.; Hanessian, S. Tetrahedron 1996, 52, 13837– 13866. (b) Patois, C.; Savignac, P. Synth. Commun. 1991, 21, 2391– 2396.

(14) (a) Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405–4408. (b) Bates, R. H.; Shotwell, J. B.; Roush, W. R. *Org. Lett.* **2008**, *10*, 4343–4346.

(15) Tortosa, M.; Yakelis, N. A.; Roush, W. R. J. Org. Chem. 2008, 73, 9657–9667.

(16) The ratio of the diastereomers was confirmed by separation the diol 22 and its diastereomers.

(17) Evans, D. A.; Bartroli, J.; Shih, T. L. J. Am. Chem. Soc. 1981, 103, 2127–2129.

(18) Koide, K.; Finkelstein, J. M.; Ball, Z.; Verdine, G. L. J. Am. Chem. Soc. 2001, 123, 398-408.